research The Functional Relevance of the Type 1 Cytokines IFN-γ and IL-2 in Alopecia Areata of C3H/HeJ Mice
IFN-γ and IL-2 are important for T cell activation in hair loss in mice.
Search
for
Sort by
Research
150-180 / 980 results 
research High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease
Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.
research Treatment of Alopecia Areata with Anti-Interferon-γ Antibodies
Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
research The Effect of Platelet Rich Plasma on Hair Re‐growth in Patients with Alopecia Areata Totalis: a Clinical Pilot Study
PRP did not significantly regrow hair in alopecia areata totalis patients.
research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
research Update on the Treatment of Alopecia Areata
Some treatments can help hair regrowth in alopecia areata, but none offer a cure, and effectiveness varies.
research Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Alopecia areata and poliosis: A retrospective analysis of 258 cases
White hairs often regrow in alopecia areata patches.
research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
research Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
research Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata
Higher CRBP1 levels are linked to more severe alopecia areata.
research Current and future pharmacotherapy for alopecia areata
New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
research Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
research The demographic and clinical profile of patients with alopecia areata in Syria: A study letter
Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Alopecia Areata: The Clinician and Patient Voice
Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Study of vitamin D deficiency in patients with alopecia areata attending a dermatology center in Iran
People with alopecia areata had lower vitamin D levels, but these levels didn't relate to many aspects of the condition.
research The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.